Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort

被引：0
|
作者：
Bigaut, K. [1 ]
Fabacher, T. [2 ]
Kremer, L. [1 ]
Ongagna, J. -C. [1 ]
Kwiat-Kowski, A. [3 ]
Sellal, F. [4 ]
Ferriby, D. [5 ]
Courtois, S. [6 ]
Vermersch, P. [7 ]
Collongues, N. [1 ]
Zephir, H. [7 ]
De Seze, J. [1 ]
Outteryck, O. [7 ]
机构：
[1] Hop Univ Strasbourg, Dept Neurol, Strasbourg, France
[2] Hop Univ Strasbourg, Grp Methode Rech Clin, Strasbourg, France
[3] Grp Hop Inst Catholique Lille, Dept Neurol, Hop St Vincent, Lille, France
[4] Hop Civils Colmar, Dept Neurol, Colmar, France
[5] Ctr Hosp Tourcoing, Dept Neurol, Tourcoing, France
[6] Grp Hosp Reg Mulhouse & Sud Alsace, Dept Neurol, Mulhouse, France
[7] Ctr Hosp Reg Univ Lille, Dept Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1013
引用
收藏
页码：536 / 536
页数：1
相关论文
共 50 条
  • [21] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [22] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
  • [23] Long-term effect of natalizumab in a French cohort of patients with RRMS: TYSTEN cohort
    Bigaut, K.
    Fabacher, T.
    Collongues, N.
    Kremer, L.
    Fleury, M. -C.
    Ongagna, J. -C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 918 - 918
  • [24] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [25] Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence
    Graham, J. B.
    Earnshaw, S. R.
    Castelli-Haley, J.
    Oleen-Burkey, M.
    Johnson, K. P.
    VALUE IN HEALTH, 2007, 10 (06) : A381 - A381
  • [26] Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
    Zecca, C.
    Roth, S.
    Findling, O.
    Perriard, G.
    Bachmann, V.
    Pless, M. L.
    Baumann, A.
    Kamm, C. P.
    Lalive, P. H.
    Czaplinski, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 640 - 640
  • [27] Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
    Zecca, C.
    Roth, S.
    Findling, O.
    Perriard, G.
    Bachmann, V.
    Pless, M. L.
    Baumann, A.
    Kamm, C. P.
    Lalive, P. H.
    Czaplinski, A.
    SWISS MEDICAL WEEKLY, 2016, 146 : 80S - 80S
  • [28] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [29] Residual adaptive inflammation in the cerebrospinal fluid after long-term natalizumab treatment in patients with relapsing-remitting multiple sclerosis
    Buhelt, Sophie
    Hansen, Malene Bredahl
    Soendergaard, Helle Bach
    El Mahdaoui, Sahla
    Hansen, Marie Mathilde
    Mahler, Mie Reith
    Christensen, Jeppe Romme
    Sellebjerg, Finn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 580 - 580
  • [30] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
12345